Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Viking Therapeutics, Inc. (VKTX)

10.92   -1.005 (-8.43%) 09-27 16:00
Open: 11.91 Pre. Close: 11.925
High: 12 Low: 10.835
Volume: 3,455,784 Market Cap: 1,092(M)

Technical analysis

as of: 2023-09-27 4:22:53 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 16.64     One year: 19.1
Support: Support1: 10.83    Support2: 9.01
Resistance: Resistance1: 14.24    Resistance2: 16.35
Pivot: 13.87
Moving Average: MA(5): 12.14     MA(20): 13.94
MA(100): 17.29     MA(250): 12.41
MACD: MACD(12,26): -0.8     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 6.1     %D(3): 5.7
RSI: RSI(14): 25.3
52-week: High: 25.71  Low: 2.61
Average Vol(K): 3-Month: 1,771 (K)  10-Days: 2,475 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VKTX ] has closed below the lower bollinger band by 0.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ VKTX ] is to continue within current trading range. Bollinger Bands are 37.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.03 - 12.1 12.1 - 12.15
Low: 10.64 - 10.73 10.73 - 10.8
Close: 10.79 - 10.92 10.92 - 11.03

Company Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Headline News

Tue, 26 Sep 2023
Should Biotechnology Stock Viking Therapeutics Inc (VKTX) Be in Your Portfolio Tuesday? - InvestorsObserver

Mon, 25 Sep 2023
Noteworthy Monday Option Activity: CNK, VKTX, CVX - Nasdaq

Mon, 25 Sep 2023
Oversold Conditions For Viking Therapeutics (VKTX) - Nasdaq

Mon, 25 Sep 2023
7 Diabetes and Weight Loss Drug Stocks With Big Potential - WTOP

Sun, 24 Sep 2023
Level Four Advisory Services LLC Buys 39342 Shares of Viking ... - MarketBeat

Sat, 16 Sep 2023
Investors Purchase Large Volume of Call Options on Viking ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 100 (M)
Shares Float 94 (M)
% Held by Insiders 5.8 (%)
% Held by Institutions 68.7 (%)
Shares Short 12,910 (K)
Shares Short P.Month 11,840 (K)

Stock Financials

EPS -0.9
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.85
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -17.4
Return on Equity (ttm) -26.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -61 (M)
Levered Free Cash Flow -35 (M)

Stock Valuations

PE Ratio -12.14
PEG Ratio -0.5
Price to Book value 2.82
Price to Sales 0
Price to Cash Flow -18.06

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.